Opus Genetics Inc. (OCUP) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Opus Genetics Inc. (OCUP:NASDAQ), powered by AI.

Current Price
$3.92
P/E Ratio
-8.5
Market Cap
85M
Sector
Healthcare
What is the Opus Genetics Inc. stock price forecast?

Opus Genetics Inc. is currently trading at $3.92. View real-time AI analysis on Alpha Lenz.

What is Opus Genetics Inc. insider trading activity?

View the latest insider trading data for Opus Genetics Inc. on Alpha Lenz.

What is Opus Genetics Inc.'s P/E ratio?

Opus Genetics Inc.'s P/E ratio is -8.5.

Opus Genetics Inc.

NASDAQ · OCUP
$3.92-0.13(-3.09%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Opus Genetics Inc.'s future dividend policy...
Alpha Chat Insight

Opus Genetics Inc. trades at a P/E of -8.5 (undervalued) with modest ROE of -20.8%.

Ask for details

Company Overview

Opus Genetics Inc. is a biotechnology company focusing on developing innovative gene therapies for inherited retinal diseases. Their primary mission is to address unmet medical needs for patients suffering from these rare genetic conditions that often lead to severe visual impairment or blindness. Opus Genetics leverages advanced gene therapy techniques to design and deliver solutions that target the root causes of such vision disorders. By concentrating on the sensory system, particularly the eyes, they aim to restore vision or significantly stall disease progression. The company operates at the intersections of genetic research, clinical development, and ophthalmology, influencing the broader healthcare and medical research sectors. As part of a niche but crucial industry within biotechnology, Opus Genetics plays a significant role in pioneering treatments that could potentially transform the lives of those affected by genetic ocular diseases. Their work underscores the vital importance of breakthrough biomedical research and innovation in improving quality of life for patients with chronic and debilitating conditions.

CEOMr. George Magrath M.B.A., M.D., M.S.
SectorHealthcare
IndustryBiotechnology
Employees18

Company Statistics

FY 2023

Profile

$84.52MMarket Cap
$19.05MRevenue
0.00Shares Out
18Employees

Margins

N/AGross
-52.75%EBITDA
-55.45%Operating
-52.36%Pre-Tax
-52.42%Net

Valuation

-8.46P/E
1.69P/B
4.44EV/Sales
-3.39EV/EBITDA
-76.01P/FCF

Growth (CAGR)

N/ARev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-19.40%ROA
-20.77%ROE
-19.38%ROIC

Financial Health

$50.50MCash & Cash Equivalents
$-46.46MNet Debt
8.10%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Opus Genetics Inc. (ticker: OCUP) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 18 employees. Market cap is $85M.

The current price is $3.915 with a P/E ratio of -8.46x and P/B of 1.69x.

ROE is -20.77% and operating margin is -55.45%. Annual revenue is $19M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Opus Genetics Inc. (OCUP) Stock Forecast 2026 $3.92 — Price, Financials & Analyst Targets | Alpha Lenz